Should we consider aldosterone as the primary screening target for preventing cardiovascular events?
Authors:
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Evidence for an increased rate of cardiovascular events in patients with primary aldosteronismJACC, 2005
- Effect of Aldosterone Antagonism on Myocardial Dysfunction in Hypertensive Patients With Diastolic Heart FailureCirculation, 2004
- Mechanisms of HypertensionJournal of the American Society of Nephrology, 2004
- Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatmentHeart, 2004
- Serum Aldosterone and the Incidence of Hypertension in Nonhypertensive PersonsNew England Journal of Medicine, 2004
- Primary aldosteronism—careful investigation is essential and rewardingMolecular and Cellular Endocrinology, 2004
- Review of aldosterone- and angiotensin II-induced target organ damage and preventionCardiovascular Research, 2004
- Spironolactone inchronic heart failure:all’s well that ends wellJACC, 2003
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999